2025 — ANA positivity in JHS/hEDS (n=289)

One-paragraph summary

Clinical-cohort study of 289 patients with joint hypermobility syndrome / hypermobile Ehlers-Danlos syndrome (JHS/hEDS) tested for anti-nuclear antibodies via Hep2 immunofluorescence and reactivity to common nuclear autoantigens via Multiplex assay. Of 210 patients with Beighton score > 5, 131 (62%) had positive ANA. Of these, 20 (15%) had a systemic autoimmune inflammatory disease (SAID+); 111 (85%) did not (SAID-). Speckled staining was most common in both subgroups (75% / 73%). In the ANA+SAID- subgroup, the target of nuclear autoreactivity remained elusive in 80%. For the project, this paper documents the autoimmunity-hypermobility overlap directly — bridging the new B26 bridge (EDS / hypermobility ↔ FM via shared dysautonomia + SFN + ANA) with quantitative autoantibody data.

Claims as triples

• autoantibody_mediated_pain — present_in → hypermobility_spectrum [evidence: 62% ANA+ in n=289 JHS/hEDS cohort; confidence: emerging]
• hypermobility_spectrum — bridges → fm_autoimmune [evidence: shared ANA-positivity + clinical-overlap framework; confidence: bridging]

Triangulation notes

• First quantitative ANA-prevalence anchor for the B26 (EDS/hypermobility) bridge that was added today from the over-regulation audit recommendation.
• The 80% "elusive nuclear autoantigen target" finding parallels the project's open Q1 (antigen target of pathogenic IgG in Goebel-type FM, narrowed to FABP7+ SGC by Seefried 2025). Both populations have autoantibodies of unclear specific target — candidate shared mechanism worth investigating.
• Discovered via Probe 5 (EDS/hypermobility); scored ingestion-worthy; promoted in Recommendation 3.